BioStock: Lipum steps up ahead of phase II – clear signals in Q3
Lipum’s Q3 report shows that the company has taken several important steps toward the planned phase II study with SOL-116. With strengthened scientific evidence, regulatory preparations and a proposed merger with its principal shareholder Flerie, the company is approaching a strategic shift in the development of its rheumatoid arthritis candidate.
Read the full article at biostock.se:
Lipum steps up ahead of phase II – clear signals in Q3
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/